A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Infectious Diseases

• Publication date

  2007-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/519265PMID 17599306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on the changing epidemiology of Clostridium difficile-associated disease

  2008cited by this paper
• Changing Epidemiology of Clostridium difficile-Associated Disease in Children

  2007cited by this paper
• Clostridium difficile-associated disease: new challenges from an established pathogen.

  2006cited by this paper
• Diarrhea etiology in a Children's Hospital Emergency Department: a prospective cohort study.

  2006cited by this paper
• Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.

  2006cited by this paper
• Changing Epidemiology of Clostridium difficile-Associated Disease: Experience and Perception of Infectious Diseases Consultants

  2006cited by this paper
• An epidemic, toxin gene-variant strain of Clostridium difficile.

  2005cited by this paper
• A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes.

  2005cited by this paper
• Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

  2005cited by this paper
• A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

  2005cited by this paper
• Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

  2005cited by this paper
• Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

  2005cited by this paper
• Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?

  2005cited by this paper
• Guidelines for the Diagnosis and Management of Clostridium dfficile-Associated Diarrhea and Colitis

  2005cited by this paper
• The new Clostridium difficile--what does it mean?

  2005cited by this paper
• Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005.

  2005cited by this paper
• Factors Associated With Failure of Metronidazole in Clostridium difficile–associated Disease

  2004cited by this paper
• Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

  2004cited by this paper
• Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001.

  2004cited by this paper
• Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin

  2002cited by this paper
• Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus

  2002cited by this paper
• Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications

  2002cited by this paper
• Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

  2000cited by this paper
• Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics

  1999cited by this paper
• Factors associated with prolonged symptoms and severe disease due to Clostridium difficile.

  1999cited by this paper
• Risk factors for early recurrent Clostridium difficile-associated diarrhea.

  1998cited by this paper
• ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease.

  1998cited by this paper
• Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation

  1998cited by this paper
• Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.

  1997cited by this paper
• Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.

  1997cited by this paper
• Prognostic criteria in Clostridium difficile colitis.

  1996cited by this paper
• Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study.

  1996cited by this paper
• Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.

  1996cited by this paper
• Clostridium Difficile-Associated Diarrhea and Colitis

  1995cited by this paper
• SevereClostridium difficile colitis

  1995cited by this paper
• Recommendations for Preventing the Spread of Vancomycin Resistance

  1995cited by this paper
• Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).

  1995cited by this paper
• Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea.

  1994cited by this paper
• Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism.

  1994cited by this paper
• Community-acquired pneumonia due to Legionella gormanii.

  1994cited by this paper
• Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci

  1993cited by this paper
• A Cluster of Vancomycin-Resistant Enterococcus faecium in an Intensive Care Unit

  1992cited by this paper
• A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit.

  1992cited by this paper
• Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

  1986cited by this paper
• Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

  1983cited by this paper
• In vitro susceptibility of anaerobic bacteria to nitroimidazoles.

  1981cited by this paper
• 12 month follow-up of mebendazole therapy for onchocerciasis.

  1981cited by this paper

• Clinical Utility of the MN Severity Criteria in Predicting Recurrent Clostridioides difficile Infection.

  2026cites this paper
• Metronidazole Research: Historical Developments and Future Directions

  2026cites this paper
• Recognition, Diagnosis, and Treatment of Clostridioides difficile Enterocolitis Presenting Without Diarrhea: A Literature Review

  2025cites this paper
• Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  2025cites this paper
• Comparative effectiveness of different therapies for Clostridioides difficile infection in adults: a systematic review and network meta-analysis of randomized controlled trials

  2025cites this paper
• Burden of Clostridioides difficile Infection and Risk Factors for Recurrences in an Italian Tertiary Care University Hospital: A Prospective Observational Study

  2025cites this paper
• Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management

  2025influential citation
• Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection

  2025cites this paper
• Human Milk Oligosaccharide Lacto-N-Neotetraose Promotes Gut Microbiota Recovery in the Context of Antibiotic-Induced Dysbiosis.

  2025cites this paper
• Management of severe and fulminant Clostridioides difficile infection in adults

  2025cites this paper
• Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10)

  2025cites this paper
• Usage of oral vancomycin for acute Clostridioides difficile infection (CDI) resulting in later acquisitions of vancomycin-resistant enterococci (VRE)

  2025cites this paper
• Healthcare-Associated Clostridioides difficile Infection: A Hospital-Based Retrospective Study in North Eastern Romania

  2025cites this paper
• Advances in the Medical Treatment of Clostridioides difficile Infection.

  2025cites this paper
• Severe form of an acute schistosomiasis with involvement of the gastrointestinal tract and lungs complicated by Clostridioides difficile infection

  2025cites this paper
• Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand

  2025cites this paper
• The impact of YabG mutations on C. difficile spore germination and processing of spore substrates

  2024cites this paper
• Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study

  2024cites this paper
• Comparative effectiveness of vancomycin and metronidazole on event-free survival after initial infection in patients with Clostridioides difficile - a German multicentre cohort study (IBIS).

  2024cites this paper
• Treatment outcomes of mild to moderate Clostridioides difficile infection in inflammatory bowel disease: an Australian experience

  2024cites this paper
• Management of Clostridioides difficile infection: an Italian Delphi consensus

  2024cites this paper
• Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update

  2024influential citation
• The Impact of YabG Mutations on Clostridioides difficile Spore Germination and Processing of Spore Substrates

  2024cites this paper
• Characterization of heparin interactions with Clostridioides difficile toxins and its potential as anti-CDI therapeutics.

  2024cites this paper
• Predicting Clostridioides difficile infection outcomes with explainable machine learning

  2024cites this paper
• Predicting clinical trial success for Clostridium difficile infections based on preclinical data

  2024cites this paper
• Clostridioides difficile infection: an update.

  2024cites this paper
• The always evolving diagnosis and management of Clostridioides difficile colitis: What you need to know

  2024cites this paper
• Comparative effectiveness of treatments for recurrent Clostridioides difficile infection: a network meta-analysis of randomized controlled trials

  2024cites this paper
• Prominent Classes of Antibiotics and their Mechanism of Resistance against Methicillin-Resistant Staphylococcus aureus

  2024cites this paper
• Review article: The epidemiology and management of Clostridioides difficile infection—A clinical update

  2024cites this paper
• Clostridioides difficile Infection: Diagnosis and Treatment Challenges

  2024cites this paper
• Antibiotic Resistances of Clostridioides difficile.

  2024cites this paper
• Clostridioides difficile Infection in Kidney Transplant Recipients

  2024cites this paper
• Efficacy Assessment of the Co-Administration of Vancomycin and Metronidazole in Clostridioides difficile-Infected Mice Based on Changes in Intestinal Ecology

  2024cites this paper
• Guidelines for Antibiotics Prescription in Critically Ill Patients

  2024cites this paper
• Improving Clostridioides difficile Infectious Disease Treatment Response via Adherence to Clinical Practice Guidelines

  2024cites this paper
• Clostridioides difficile

  2024cites this paper
• Systemic Absorption of Oral and Rectal Vancomycin in a Critically Ill Patient: A Case Report

  2024cites this paper
• A Review of Therapies for Clostridioides difficile Infection

  2024influential citation
• Complex Management of a Geriatric Patient With Multimorbidity: A Case Study

  2024cites this paper
• Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options

  2024cites this paper
• Clinical Efficacy of Therapeutic Agents for Clostridioides difficile Infection Based on Four Severity Classifications.

  2024cites this paper
• Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence

  2024influential citation
• Reduced Vancomycin Susceptibility in Clostridioides difficile is Associated with Lower Rates of Initial Cure and Sustained Clinical Response.

  2024cites this paper
• Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group

  2024cites this paper
• Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat?

  2024cites this paper
• S2k-Leitlinie Gastrointestinale Infektionen der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

  2024cites this paper
• Impact of an Intervention Program on Clostridioides difficile Infections: Comparison of 2 Hospital Cohorts

  2024cites this paper
• Infección por Clostridioides difficile en el adulto

  2024cites this paper
• Clostridioides difficile Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis

  2023cites this paper
• Clostridium difficile in inflammatory bowel disease

  2023cites this paper
• Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence of Clostridioides difficile infection: a propensity score analysis.

  2023cites this paper
• Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

  2023cites this paper
• Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer

  2023cites this paper
• Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies

  2023cites this paper
• Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review

  2023cites this paper
• Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018

  2023cites this paper
• Preservation of the Innate Immune Response to Clostridioides difficile Infection in Hospitalized Immunocompromised Patients

  2023influential citation
• Impact of Nucleic Acid Amplification Test on Clinical Outcomes in Patients with Clostridioides difficile Infection

  2023cites this paper
• Efficacy of bezlotoxumab in preventing recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.

  2023cites this paper
• Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.

  2023cites this paper
• Clostridioides difficile PCR Tcdb Cycle Threshold predicts toxin EIA positivity but not severity of infection.

  2023cites this paper
• Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future.

  2023cites this paper
• Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection

  2023cites this paper
• Management of Severe Colitis and Toxic Megacolon

  2023cites this paper
• Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo

  2023cites this paper
• Risk factors for Recurrent Clostridioides Difficile Infection in Children.

  2023cites this paper
• Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient

  2023cites this paper
• Incidence and risk factors for recurrent Clostridioides difficile infection in pediatric at-risk groups in selected Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) hospitals

  2023cites this paper
• The Effect of Antibiotic Therapy for Clostridioides difficile Infection on Mortality and Other Patient-Relevant Outcomes: a Systematic Review and Meta-analysis.

  2023cites this paper
• Vancomycin vs metronidazole use for the treatment of Clostridioides difficile infection in a tertiary care hospital in Saudi Arabia

  2023cites this paper
• Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting

  2023influential citation
• Characteristics and outcomes of Clostridioides difficile infection after a change in the diagnostic testing algorithm

  2023cites this paper
• Efficacy of Bezlotoxumab Against Clostridioides difficile Infection: A Case-Series Study at a University Hospital in Japan and Literature Review

  2023cites this paper
• A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection

  2023cites this paper
• A Case of Clostridioides difficile: Update on Practice Guidelines.

  2023cites this paper
• Spatial-temporal simulation for hospital infection spread and outbreaks of Clostridioides difficile

  2023cites this paper
• Infecciones por Clostridioides (Clostridium) difficile en un hospital geriátrico de Costa Rica

  2022cites this paper
• Clostridioides difficile – a new name, the old problems with diagnosis and treatment

  2022cites this paper
• Antibiotic Resistance And Microbiota Response.

  2022cites this paper
• Comparison of clinical severity, genotype and toxin gene expression of binary toxin-producing Clostridioides difficile clinical isolates in Japan

  2022cites this paper
• Risk Factors and Clinical Impact of Carbapenem-Resistant Enterobacterales Coinfections Among Hospitalized Patients with Clostridioides difficile Infection

  2022cites this paper
• Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines

  2022cites this paper
• Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection

  2022cites this paper
• The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021

  2022influential citation
• Impacts of Corticosteroid Therapy at Acute Stage of Hospital-Onset Clostridioides difficile Infections

  2022influential citation
• Reappraisal of the clinical role of metronidazole therapy for Clostridioides difficile infection in Taiwan: A multicenter prospective study.

  2022cites this paper
• Global research on Clostridium difficile-associated diarrhoea: A visualized study

  2022cites this paper
• Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease

  2022cites this paper
• Treatment and Outcomes of Clostridioides difficile Infection in Switzerland: A Two-Center Retrospective Cohort Study

  2022cites this paper
• World Journal of Gastroenterology Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental

  2022cites this paper
• Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?

  2022cites this paper
• High-Dose Vancomycin in the Treatment of Clostridioides difficile Infection

  2022influential citation
• Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients.

  2022cites this paper
• Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes

  2022cites this paper
• Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study

  2022cites this paper
• Comparison of the Risk of Recurrent Clostridioides Difficile Infections Among Patients in 2018 Versus 2013.

  2022cites this paper
• Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile

  2022cites this paper
• Neutrophil Ratio of White Blood Cells as a Prognostic Predictor of Clostridioides difficile Infection

  2022influential citation